Stryker Co. (NYSE:SYK) Stock Position Raised by NewEdge Advisors LLC

NewEdge Advisors LLC increased its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 16.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 27,487 shares of the medical technology company's stock after acquiring an additional 3,873 shares during the period. NewEdge Advisors LLC's holdings in Stryker were worth $9,897,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Kohmann Bosshard Financial Services LLC acquired a new stake in Stryker during the 4th quarter valued at $25,000. Rakuten Securities Inc. boosted its position in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after buying an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new stake in shares of Stryker during the fourth quarter worth about $30,000. BankPlus Trust Department acquired a new position in shares of Stryker in the fourth quarter worth about $33,000. Finally, VSM Wealth Advisory LLC purchased a new position in Stryker in the fourth quarter valued at about $36,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Stock Performance

NYSE:SYK traded up $10.59 during mid-day trading on Wednesday, hitting $358.71. The stock had a trading volume of 671,405 shares, compared to its average volume of 1,354,242. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a 50 day simple moving average of $369.25 and a 200-day simple moving average of $373.06. The stock has a market capitalization of $136.92 billion, a price-to-earnings ratio of 46.23, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the company earned $3.46 EPS. On average, research analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.94%. Stryker's dividend payout ratio is presently 43.30%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Truist Financial lifted their price objective on Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a report on Thursday, January 30th. Wells Fargo & Company lifted their price target on shares of Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Argus set a $450.00 price target on shares of Stryker in a report on Monday, February 3rd. Royal Bank of Canada raised their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an "outperform" rating in a report on Wednesday, January 29th. Finally, BTIG Research set a $403.00 target price on shares of Stryker and gave the stock a "buy" rating in a research report on Monday, April 14th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $423.53.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.